ALTO-101

Small molecule

On holdsponsor decision

Evidence outlook · program status

On hold (2026-04-01), after a negative readout

After the Phase 2 CIAS proof-of-concept study missed its primary endpoints (topline 1 April 2026), Alto said it does not plan to advance ALTO-101 in CIAS independently, prioritises ALTO-207, and will explore partnering a modified-release oral formulation. The trials below are the program's evidence history; no evidence signal is assigned while development is paused.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (1)
Other / comorbidity

Competitive landscape

This mechanism is crowded: 11 other tracked programmes target it, 8 of them ahead of this one.

This drug's own stage for Cognitive Impairment Associated with Schizophrenia: Stage not on record. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
ALTO-101: this drugStage not on recordSmall moleculePDE4not yet gradedNo reviewed efficacy summary in this indication
Apremilast (Otezla)
Approved(overall)
Small moleculePDE4
Reliable signal(overall)
No reviewed efficacy summary in this indication
Crisaborole (Eucrisa)
Approved(overall)
Small moleculePDE4
Reliable signal(overall)
No reviewed efficacy summary in this indication
Difamilast (Moizerto / Adquey)
Approved(overall)
Small moleculePDE4
Partial signal(overall)
No reviewed efficacy summary in this indication
Roflumilast (Daliresp)
Approved(overall)
Small moleculePDE4
not yet graded(overall)
No reviewed efficacy summary in this indication
Roflumilast (Zoryve Foam)
Approved(overall)
Small moleculePDE4
not yet graded(overall)
No reviewed efficacy summary in this indication
Roflumilast (Zoryve)
Approved(overall)
Small moleculePDE4
Reliable signal(overall)
No reviewed efficacy summary in this indication
Mufemilast
Phase 3(overall)
Small moleculePDE4
Partial signal(overall)
No reviewed efficacy summary in this indication
Prifemilast (HPP737)
Phase 3(overall)
Small moleculePDE4
Partial signal(overall)
No reviewed efficacy summary in this indication
Inidascamine (RL-007)Phase 2——not yet gradedNo reviewed efficacy summary in this indication
Morcamilast
Phase 2(overall)
Small moleculePDE4
not yet graded(overall)
No reviewed efficacy summary in this indication
PALI-2108
Phase 2(overall)
Small moleculePDE4
Weak signal(overall)
No reviewed efficacy summary in this indication
Idrebormilast
Discontinued
Small moleculePDE4
Partial signal(overall)
No reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

1 April 2026Topline resultPhase 2 POC of ALTO-101 in CIAS did not reach statistical significance on its primary EEG or cognitive endpoints
Alto Neuroscience · Source ↗